Editas Medicine
Editas Medicine is a leading genomic medicine company that is focused on translating the power and potential of gene editing technologies into a new class of precision medicines. The company's mission is to develop transformative, durable, precision genomic medicines for a broad class of diseases.
History[edit | edit source]
Editas Medicine was founded in 2013 by a group of world-renowned scientists who are pioneers in genome editing. The company is headquartered in Cambridge, Massachusetts, a hub for biotechnology innovation. Since its inception, Editas Medicine has been at the forefront of developing and advancing CRISPR gene editing technologies.
Technology[edit | edit source]
Editas Medicine's technology platform is based on CRISPR-Cas9, a revolutionary gene editing system that allows for precise, directed changes to genomic DNA. CRISPR-Cas9 has been adapted from a naturally occurring genome editing system in bacteria. The bacteria capture snippets of DNA from invading viruses and use them to create DNA segments known as CRISPR arrays. The CRISPR arrays allow the bacteria to "remember" the viruses. If the viruses attack again, the bacteria produce RNA segments from the CRISPR arrays to target the viruses' DNA. The bacteria then use Cas9 or a similar enzyme to cut the DNA apart, which disables the virus.
Clinical Development[edit | edit source]
Editas Medicine is developing a robust pipeline of therapies for the treatment of serious diseases with significant unmet medical need. The company's lead program, EDIT-101, is a CRISPR-based experimental medicine under investigation for the treatment of Leber congenital amaurosis (LCA), a rare genetic disorder that leads to blindness early in life. EDIT-101 is the first in vivo (inside the body) CRISPR medicine to be administered to patients.
Future Directions[edit | edit source]
Editas Medicine continues to leverage its leading genome editing platform to develop a broad pipeline of therapies for the treatment of serious diseases with significant unmet medical need. The company is committed to discovering and developing novel medicines that can transform the lives of patients with genetically defined diseases.
See Also[edit | edit source]
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
